Publications

Edward Chu, MD

Gao C, Chen G, Zhang DH, Zhang J, Kuan SF, Hu W, Esni F, Gao X, Guan JL, Chu E, Hu J. PYK2 Is Involved in Premalignant Acinar Cell Reprogramming and Pancreatic Ductal Adenocarcinoma Maintenance by Phosphorylating β-CateninY654. Cell Mol Gastroenterol Hepatol. 2019 Jul 19; doi: 10.1016/j.jcmgh.2019.07.004. PubMed PMID: 31330317.
Garcia CA, Bhatnagar M, Rodenbach R, Chu E, Marks S, Graham-Pardus A, Kriner J, Winfield M, Minnier C, Leahy J, Hanchett S, Baird E, Arnold RM, Levenson JE. Standardization of Inpatient CPR Status Discussions and Documentation Within the Division of Hematology-Oncology at UPMC Shadyside: Results From PDSA Cycles 1 and 2. J Oncol Pract. 2019 Aug;15(8):e746-e754. doi: 10.1200/JOP.18.00416. PubMed PMID: 31206337.
Christner SM, Parise RA, Ivy PS, Tawbi H, Chu E, Beumer JH. Quantitation of paclitaxel, and its 6-alpha-OH and 3-para-OH metabolites in human plasma by LC-MS/MS. J Pharm Biomed Anal. 2019 Aug 5;17226-32. doi: 10.1016/j.jpba.2019.04.027. PubMed PMID: 31022613; PMCID: PMC6548629.
Ganguly A, Frank D, Kumar N, Cheng YC, Chu E. Cancer Biomarkers for Integrative Oncology. Curr Oncol Rep. 2019 Mar 5;21(4):32. doi: 10.1007/s11912-019-0782-6. PubMed PMID: 30834992.
Sun W, Patel A, Normolle D, Patel K, Ohr J, Lee JJ, Bahary N, Chu E, Streeter N, Drummond S. A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma. Cancer. 2019 Mar 15;125(6):902-909. doi: 10.1002/cncr.31872. PubMed PMID: 30561756; PMCID: PMC6402964.
Wei N, Li J, Fang C, Chang J, Xirou V, Syrigos NK, Marks BJ, Chu E, Schmitz JC. Targeting colon cancer with the novel STAT3 inhibitor bruceantinol. Oncogene. 2019 Mar;38(10):1676-1687. doi: 10.1038/s41388-018-0547-y. PubMed PMID: 30348989.
Lee JJ, Chu E. Recent Advances in the Clinical Development of Immune Checkpoint Blockade Therapy for Mismatch Repair Proficient (pMMR)/non-MSI-H Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2018 Dec;17(4):258-273. doi: 10.1016/j.clcc.2018.06.004. PubMed PMID: 30072278; PMCID: PMC6612427.
Beumer JH, Chu E, Allegra C, Tanigawara Y, Milano G, Diasio R, Kim TW, Mathijssen RH, Zhang L, Arnold D, Muneoka K, Boku N, Joerger M. Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy. Clin Pharmacol Ther. 2019 Mar;105(3):598-613. doi: 10.1002/cpt.1124. PubMed PMID: 29923599; PMCID: PMC6309286.
Chu E. How I treat chemorefractory metastatic colorectal cancer. Clin Adv Hematol Oncol. 2018 May;16(5):340-345. PubMed PMID: 29851930.
Liu H, Liu H, Zhou Z, Parise RA, Chu E, Schmitz JC. Herbal formula Huang Qin Ge Gen Tang enhances 5-fluorouracil antitumor activity through modulation of the E2F1/TS pathway. Cell Commun Signal. 2018 Feb 20;16(1):7. doi: 10.1186/s12964-018-0218-1. PubMed PMID: 29458395; PMCID: PMC5819251.
Xi D, Bao T, Chen Q, Chen S, Cheng YC, Cullen J, Frank DA, Friedberg JW, Kronish I, Lee JE, Levine M, Li P, Li S, Lu W, Mao JJ, O'Keefe S, Rubinstein L, Shah MA, Standish L, Paller CJ, Chu E. State of the Science: Cancer Complementary and Alternative Medicine Therapeutics Research-NCI Strategic Workshop Highlights of Discussion Report. J Natl Cancer Inst Monogr. 2017 Nov 1;2017(52): doi: 10.1093/jncimonographs/lgx003. PubMed PMID: 29140484; PMCID: PMC6061228.
Kiesel BF, Scemama J, Parise RA, Villaruz L, Iffland A, Doyle A, Ivy P, Chu E, Bakkenist CJ, Beumer JH. LC-MS/MS assay for the quantitation of the ATR kinase inhibitor VX-970 in human plasma. J Pharm Biomed Anal. 2017 Nov 30;146244-250. doi: 10.1016/j.jpba.2017.08.037. PubMed PMID: 28888173; PMCID: PMC5632222.
Matsumoto J, Kiesel BF, Parise RA, Guo J, Taylor S, Huang M, Eiseman JL, Ivy SP, Kunos C, Chu E, Beumer JH. LC-MS/MS assay for the quantitation of the ribonucleotide reductase inhibitor triapine in human plasma. J Pharm Biomed Anal. 2017 Nov 30;146154-160. doi: 10.1016/j.jpba.2017.08.036. PubMed PMID: 28881312; PMCID: PMC5636190.
Stoller R, Schmitz JC, Ding F, Puhalla S, Belani CP, Appleman L, Lin Y, Jiang Y, Almokadem S, Petro D, Holleran J, Kiesel BF, Ken Czambel R, Carneiro BA, Kontopodis E, Hershberger PA, Rachid M, Chen A, Chu E, Beumer JH. Phase I study of veliparib in combination with gemcitabine. Cancer Chemother Pharmacol. 2017 Sep;80(3):631-643. doi: 10.1007/s00280-017-3409-3. PubMed PMID: 28770300; PMCID: PMC5734661.
Schenker Y, Bahary N, Claxton R, Childers J, Chu E, Kavalieratos D, King L, Lembersky B, Tiver G, Arnold RM. A Pilot Trial of Early Specialty Palliative Care for Patients with Advanced Pancreatic Cancer: Challenges Encountered and Lessons Learned. J Palliat Med. 2018 Jan;21(1):28-36. doi: 10.1089/jpm.2017.0113. PubMed PMID: 28772092; PMCID: PMC5757080.
Atreya CE, Yaeger R, Chu E. Systemic Therapy for Metastatic Colorectal Cancer: From Current Standards to Future Molecular Targeted Approaches. Am Soc Clin Oncol Educ Book. 2017;37246-256. doi: 10.1200/EDBK_175679. PubMed PMID: 28561718.
Kunos CA, Chu E, Makower D, Kaubisch A, Sznol M, Ivy SP. Phase I Trial of Triapine-Cisplatin-Paclitaxel Chemotherapy for Advanced Stage or Metastatic Solid Tumor Cancers. Front Oncol. 2017;762. doi: 10.3389/fonc.2017.00062. PubMed PMID: 28421163; PMCID: PMC5378786.
Lee JJ, Chu E. Adjuvant Chemotherapy for Stage II Colon Cancer: The Debate Goes On. J Oncol Pract. 2017 Apr;13(4):245-246. doi: 10.1200/JOP.2017.022178. PubMed PMID: 28399385; PMCID: PMC5455155.
Niu J, Scheuerell C, Mehrotra S, Karan S, Puhalla S, Kiesel BF, Ji J, Chu E, Gopalakrishnan M, Ivaturi V, Gobburu J, Beumer JH. Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients With BRCA 1/2-Mutated Cancer or PARP-Sensitive Tumor Types. J Clin Pharmacol. 2017 Aug;57(8):977-987. doi: 10.1002/jcph.892. PubMed PMID: 28387939; PMCID: PMC5503785.
Lee JJ, Chu E. Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS-102). Clin Colorectal Cancer. 2017 Jun;16(2):85-92. doi: 10.1016/j.clcc.2017.01.003. PubMed PMID: 28242161; PMCID: PMC5743195.
Kunos CA, Chu E, Beumer JH, Sznol M, Ivy SP. Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies. Cancer Chemother Pharmacol. 2017 Jan;79(1):201-207. doi: 10.1007/s00280-016-3200-x. PubMed PMID: 27878356; PMCID: PMC5226891.
Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV Jr, Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y. ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open. 2016;1(5):e000097. doi: 10.1136/esmoopen-2016-000097. PubMed PMID: 27843641; PMCID: PMC5070299.
Parikh RA, Appleman LJ, Beumer JH, Matczak E, Chu E. Tyrosine Kinase and Mammalian Target of Rapamycin Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Practical Clinical Implications of Pharmacologic Features. Clin Genitourin Cancer. 2017 Feb;15(1):7-22. doi: 10.1016/j.clgc.2016.05.011. PubMed PMID: 27473523.
Lee JJ, Beumer JH, Chu E. Therapeutic drug monitoring of 5-fluorouracil. Cancer Chemother Pharmacol. 2016 Sep;78(3):447-64. doi: 10.1007/s00280-016-3054-2. PubMed PMID: 27217046; PMCID: PMC5204259.
Lee JJ, Seraj J, Yoshida K, Mizuguchi H, Strychor S, Fiejdasz J, Faulkner T, Parise RA, Fawcett P, Pollice L, Mason S, Hague J, Croft M, Nugteren J, Tedder C, Sun W, Chu E, Beumer JH. Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry. Cancer Chemother Pharmacol. 2016 Mar;77(3):515-26. doi: 10.1007/s00280-016-2965-2. PubMed PMID: 26787503; PMCID: PMC4767595.
Wu S, Guo Z, Hopkins CD, Wei N, Chu E, Wipf P, Schmitz JC. Bis-cyclopropane analog of disorazole C1 is a microtubule-destabilizing agent active in ABCB1-overexpressing human colon cancer cells. Oncotarget. 2015 Dec 1;6(38):40866-79. doi: 10.18632/oncotarget.5885. PubMed PMID: 26506423; PMCID: PMC4747374.
Soni A, Chu E. Cost-Effectiveness of Adjuvant Chemotherapy in the Treatment of Early-Stage Colon Cancer. Clin Colorectal Cancer. 2015 Dec;14(4):219-26. doi: 10.1016/j.clcc.2015.05.002. PubMed PMID: 26072443.
Parikh RA, Wang P, Beumer JH, Chu E, Appleman LJ. The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment. Onco Targets Ther. 2014;7969-83. doi: 10.2147/OTT.S40241. PubMed PMID: 24959084; PMCID: PMC4061161.
Lee JJ, Chu E. Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer. Clin Colorectal Cancer. 2014 Sep;13(3):135-44. doi: 10.1016/j.clcc.2014.02.001. PubMed PMID: 24768040.

<< Investigators Search

Top